Abstract
Get full access to this article
View all access options for this article.
References
1.Recommended vaccinations for adults . U.S. Centers for Disease Control and Prevention . Accessed October 22, 2024 . https://www.cdc.gov/vaccines/imz-schedules/adult-easyread.html
2.
Gerber
S.
Arexvy (adjuvanted RSVPreF3) 2-year update. ACIP presentation slides: June 26-28 , 2024 . Accessed October 22, 2024 . https://bit.ly/4ciO7hH
3.
Munjal
I.
RSVpreF adult clinical development update. ACIP presentation slides: June 26-28 , 2024 . Accessed October 22, 2024 . https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/02-RSV-Adult-Munjal-508.pdf
4.
Das
R.
Update on moderna’s RSV vaccine, mRESVIA (mRNA-1345), in adults ≥60 years of age, advisory committee on immunization practices . Accessed October 22, 2024 . https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/04-RSV-Adult-Das-508.pdf
5.ABRYSVO (Respiratory syncytial virus vaccine) [prescribing information] . Pfizer Labs; August 2024 .
6.AREXVY (Respiratory syncytial virus vaccine, adjuvanted)[prescribing information] . GlaxoSmithKline; June 2024 .
7.MRESVIA (Respiratory syncytial virus vaccine) . Accessed October 22, 2024
https://www.fda.gov/media/179005/download
8.
Britton
A
Roper
LE
Kotton
CN
, et al Use of respiratory syncytial virus vaccines in adults aged ≥60 years: updated recommendations of the advisory committee on immunization practices—United States, 2024 . MMWR Morb Mortal Wkly Rep . 2024 ;73 :696 -702 . doi:10.15585/mmwr.mm7332e1